
INDEPENDENT RESEARCH MEDIA HOUSE FOR THE ASX. DEPTH OVER HYPE.
Samso Insights
Long-form analysis of commodities, markets and themes.
LATEST INSIGHT
Recce Pharmaceuticals' synthetic antibiotic R327, what its Phase 3 trials have and have not shown, the Arrotex licence, and the cash, debt and AGM.
5 NOV 2026 · 37 MIN READ
SAMSO INSIGHTS
Data centres in Australia, and where a new one could go. Sydney, Melbourne, Brisbane and Perth compared on power, the grid queue, prices and planning.
4 NOV 2026 · 28 MIN READ
SAMSO INSIGHTS
Island Pharmaceuticals (ASX ILA) is taking galidesivir to the FDA for Marburg. We cover the monkey data, the Ebola outbreak, the timeline and the...
4 NOV 2026 · 34 MIN READ
SAMSO INSIGHTS
3 NOV 2026
SAMSO INSIGHTS
30 OCT 2026
SAMSO INSIGHTS
21 OCT 2026 MEMBERS ONLY
SAMSO INSIGHTS
3 NOV 2026
SAMSO INSIGHTS
28 OCT 2026
SAMSO INSIGHTS
19 OCT 2026
"The information or opinions provided herein do not constitute investment advice, an offer or solicitation to subscribe for, purchase or sell the investment product(s) mentioned herein. It does not take into consideration, nor have any regard to your specific investment objectives, financial situation, risk profile, tax position and particular, or unique needs and constraints." - Read full disclaimer.
What do you get as a Samso Member?
- New Samso Insights in your inbox, free. Long-form analysis of commodities, markets and themes.
- Research notes on ASX companies. Every note declares whether it was commissioned.
- Conversations with the people running ASX companies, through Coffee with Samso.
- No price targets, no valuations and no buy, sell or hold calls.
- You can leave any time.














